Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416403 | 0.81 | ATM (0.43) | MAPTALDH1A1KMT2AHPGDHSD17B10 | |
| SCHEMBL25384931 | 0.81 | ATM (0.43) | MAPTALDH1A1KMT2AHPGDHSD17B10 | |
| SCHEMBL19137249 | 0.76 | HPGD (0.42) | SMN1; SMN2TSHRMAPTALDH1A1NPSR1 | |
| SCHEMBL2901203 | 0.75 | SMN1; SMN2 (0.41) | SMN1; SMN2TSHRMAPTALDH1A1NPSR1 | |
| SCHEMBL19548912 | 0.75 | GRIK1 (0.33) | TSHRLMNA | |
| SCHEMBL28887297 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRMAPTALDH1A1NPSR1 | |
| SCHEMBL14691340 | 0.72 | GRIK1 (0.32) | — | |
| SCHEMBL9213342 | 0.71 | TSHR (0.47) | SMN1; SMN2TSHRMAPTALDH1A1NPSR1 | |
| SCHEMBL8638571 | 0.70 | SMN1; SMN2 (0.38) | SMN1; SMN2TSHRMAPTALDH1A1NPSR1 | |
| SCHEMBL29988 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | SMN1; SMN2 3860/4885TSHR 2947/4885MAPT 4508/4885 |
| US-20090306066-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DHPS, PADI3 | SMN1; SMN2 3262/4885TSHR 3052/4885MAPT 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.